04 Nov 2025 | 5 Mins Read
Glenmark to Launch New Acid-Producing Enzyme Inhibitor Injection
Flipitmoney
Glenmark Pharmaceuticals' US arm will launch 8.4% Sodium Bicarbonate Injection USP in November 2025, treating metabolic acidosis caused by excess acid production in the body. The product is bioequivalent and therapeutically equivalent to Abbott Laboratories' reference listed drug and achieved $63.8 million annual sales from August 2024 to August 2025, market data shows.